Nicorandil, a Nitric Oxide Donor and ATP-Sensitive Potassium Channel Opener, Protects Against Dystrophin-Deficient Cardiomyopathy

J Cardiovasc Pharmacol Ther. 2016 Nov;21(6):549-562. doi: 10.1177/1074248416636477. Epub 2016 Mar 2.

Abstract

Background: Dystrophin-deficient cardiomyopathy is a growing clinical problem without targeted treatments. We investigated whether nicorandil promotes cardioprotection in human dystrophin-deficient induced pluripotent stem cell (iPSC)-derived cardiomyocytes and the muscular dystrophy mdx mouse heart.

Methods and results: Dystrophin-deficient iPSC-derived cardiomyocytes had decreased levels of endothelial nitric oxide synthase and neuronal nitric oxide synthase. The dystrophin-deficient cardiomyocytes had increased cell injury and death after 2 hours of stress and recovery. This was associated with increased levels of reactive oxygen species and dissipation of the mitochondrial membrane potential. Nicorandil pretreatment was able to abolish these stress-induced changes through a mechanism that involved the nitric oxide-cyclic guanosine monophosphate pathway and mitochondrial adenosine triphosphate-sensitive potassium channels. The increased reactive oxygen species levels in the dystrophin-deficient cardiomyocytes were associated with diminished expression of select antioxidant genes and increased activity of xanthine oxidase. Furthermore, nicorandil was found to improve the restoration of cardiac function after ischemia and reperfusion in the isolated mdx mouse heart.

Conclusion: Nicorandil protects against stress-induced cell death in dystrophin-deficient cardiomyocytes and preserves cardiac function in the mdx mouse heart subjected to ischemia and reperfusion injury. This suggests a potential therapeutic role for nicorandil in dystrophin-deficient cardiomyopathy.

Keywords: cardiomyopathy; induced pluripotent cells; muscular dystrophy; nicorandil.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Cardiomyopathies / genetics
  • Cardiomyopathies / metabolism
  • Cardiomyopathies / physiopathology
  • Cardiomyopathies / prevention & control*
  • Cell Line
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Humans
  • Induced Pluripotent Stem Cells / drug effects*
  • Induced Pluripotent Stem Cells / metabolism
  • Induced Pluripotent Stem Cells / pathology
  • KATP Channels / agonists*
  • KATP Channels / metabolism
  • Male
  • Mice, Inbred mdx
  • Mitochondria, Heart / drug effects
  • Mitochondria, Heart / metabolism
  • Mitochondria, Heart / pathology
  • Muscular Dystrophy, Animal / drug therapy*
  • Muscular Dystrophy, Animal / genetics
  • Muscular Dystrophy, Animal / metabolism
  • Myocardial Reperfusion Injury / genetics
  • Myocardial Reperfusion Injury / metabolism
  • Myocardial Reperfusion Injury / physiopathology
  • Myocardial Reperfusion Injury / prevention & control*
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • Nicorandil / metabolism
  • Nicorandil / pharmacology*
  • Nitric Oxide / metabolism*
  • Nitric Oxide Donors / metabolism
  • Nitric Oxide Donors / pharmacology*
  • Oxidative Stress / drug effects
  • Reactive Oxygen Species / metabolism
  • Recovery of Function
  • Signal Transduction / drug effects
  • Ventricular Function, Left / drug effects
  • Xanthine Oxidase / metabolism

Substances

  • KATP Channels
  • Nitric Oxide Donors
  • Reactive Oxygen Species
  • Nicorandil
  • Nitric Oxide
  • Xanthine Oxidase